MARKET

AKCA

AKCA

Akcea
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.15
+0.01
+0.06%
Closed 16:29 09/18 EDT
OPEN
18.12
PREV CLOSE
18.14
HIGH
18.21
LOW
18.12
VOLUME
957.88K
TURNOVER
--
52 WEEK HIGH
22.79
52 WEEK LOW
8.00
MARKET CAP
1.84B
P/E (TTM)
-21.2654
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average AKCA stock price target is 23.33 with a high estimate of 41.00 and a low estimate of 16.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AKCA
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Akcea Therapeutics Inc stock information, including NASDAQ:AKCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKCA stock methods without spending real money on the virtual paper trading platform.